Cure My Disease

Don't miss your cure!

 Log in / Sign up

New HER2-Targeting drug shows promise in early cancer trial

NCT ID NCT05872295

Recruiting now Disease control Sponsor: Iksuda Therapeutics Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests IKS014, a drug designed to seek out and destroy HER2-positive cancer cells, in people with advanced solid tumors like breast, stomach, and gastroesophageal cancers. The main goals are to find the safest dose and check for early signs of tumor shrinkage. About 165 participants will receive the drug intravenously, and researchers will monitor side effects and how the body processes the treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm esophageal adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma HER2 positive breast carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CANCER

Contacts and locations

Locations

  • Alfred Health

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Auckland City Hospital

    RECRUITING

    Auckland, New Zealand

  • Concord Repatriation General Hospital Medical Oncology Clinical Trials Unit

    RECRUITING

    Concord, New South Wales, 2139, Australia

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Hoag Memorial Hospital Presbyterian

    RECRUITING

    Newport Beach, California, 92663, United States

  • Linear Clinical Research

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Macquarie University

    RECRUITING

    Sydney, New South Wales, 2109, Australia

  • National Cancer Centre Singapore

    RECRUITING

    Singapore, Singapore

  • Peninsula & South Eastern Haematology and Oncology Group (PSEHOG)

    RECRUITING

    Frankston, Victoria, 3199, Australia

  • START Dallas - Fort Worth

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • Tan Tock Seng Hospital

    RECRUITING

    Singapore, Singapore

  • Tennessee Oncology

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Westmead Hospital

    RECRUITING

    Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.